Literature DB >> 1866690

Indicators of prognosis after hepatic resection for colorectal secondaries.

J Scheele1, R Stangl, A Altendorf-Hofmann, F P Gall.   

Abstract

From 1960 to 1988, 266 patients underwent resection of colorectal secondaries to the liver with curative intent. All patients were followed until April 1, 1990, or death, with a median follow-up time of 52 months. Nine patients with minimal macroscopic residual disease and 38 patients with all gross tumor removed but positive margins showed a poor prognosis with a median survival time of 13.3 months, the longest being 42 months. Of the 219 patients having potentially curative resection, 12 patients died postoperatively (5.5%). Actuarial 5, 10 and 20-year survival for the remaining 207 patients was 39%, 28%, and 18%, respectively. At April 1, 1990, 77 patients were alive with no evidence of disease for up to 24 years, and 12 patients had died without recurrence. The following factors were associated with less favorable crude survival: presence and extent of mesenteric lymph node involvement (p = 0.0003), grade III/IV primary tumor (p = 0.035), synchronous diagnosis of metastases (p = 0.017), satellite metastases (p = 0.0003), limited resection margins (p = 0.019), and nonanatomic procedures (p = 0.013). With respect to disease-free survival, grading of the primary (p = 0.055) and the extent of clear margins (p = 0.019) failed to achieve statistical significance. Two other criteria are commonly recommended as absolute contraindications to hepatic resection: extrahepatic disease and the presence of four or more independent metastases. A radical excision of all detectable disease may rarely be possible in these circumstances. Nevertheless, within the curative settings, no significant predictive value regarding either overall or disease-free survival was found in this series. Three corresponding "high risk" patients are alive without disease at 5 to 11 years from hepatic resection. These patients with more advanced intrahepatic or concomitant limited extrahepatic disease require a particularly thorough diagnostic work up. As no superior therapeutic alternative is currently available, an aggressive surgical approach may occasionally be justified, and may, in a small portion, result in definite tumor control.

Entities:  

Mesh:

Year:  1991        PMID: 1866690

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  117 in total

1.  Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor.

Authors:  P A Clavien; M Selzner; M A Morse
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

Review 2.  Ablative therapy for liver tumours.

Authors:  E A Dick; S D Taylor-Robinson; H C Thomas; W M W Gedroyc
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

3.  LIVER RESECTION FOR METASTASES FROM COLORECTAL CANCER.

Authors:  H G Mukhopadhyay; L S Vohra; A K Sharma; R Solanki; P S Reddy; G S Chopra; P Subhas
Journal:  Med J Armed Forces India       Date:  2017-06-26

4.  Clinical risk score can be used to select patients for staging laparoscopy and laparoscopic ultrasound for colorectal liver metastases.

Authors:  A J Shah; J Phull; M D Finch-Jones
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

5.  Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases.

Authors:  Eduardo de Santibañes; Diego Fernandez; Carlos Vaccaro; Guillermo Ojea Quintana; Fernando Bonadeo; Juan Pekolj; Carlos Bonofiglio; Ernesto Molmenti
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

6.  Liver Metastases.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-02

7.  Hypofractionated radiotherapy with tomotherapy for patients with hepatic oligometastases: retrospective analysis of two institutions.

Authors:  Jong Hoon Lee; Joo Hwan Lee; Hong Seok Jang; Hyo Chun Lee; Jung Won Lee; Dae Gyu Kang; Byoung Yong Shim; Bong-Hyeon Kye; Hyung Jin Kim; Hyeon-Min Cho; Young Jin Suh; Sung Hwan Kim
Journal:  Clin Exp Metastasis       Date:  2013-02-06       Impact factor: 5.150

8.  Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?

Authors:  Nir Lubezky; Ravit Geva; Einat Shmueli; Richard Nakache; Joseph M Klausner; Arie Figer; Menahem Ben-Haim
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

9.  Analysis of preoperative prognostic factors for long-term survival after hepatic resection of liver metastasis of colorectal carcinoma.

Authors:  Atsushi Sasaki; Yukio Iwashita; Kohei Shibata; Toshifumi Matsumoto; Masayuki Ohta; Seigo Kitano
Journal:  J Gastrointest Surg       Date:  2005-03       Impact factor: 3.452

10.  Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Authors:  René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.